NO902995L - Stabilisert fgf sammensetning samt fremstilling derav. - Google Patents

Stabilisert fgf sammensetning samt fremstilling derav.

Info

Publication number
NO902995L
NO902995L NO90902995A NO902995A NO902995L NO 902995 L NO902995 L NO 902995L NO 90902995 A NO90902995 A NO 90902995A NO 902995 A NO902995 A NO 902995A NO 902995 L NO902995 L NO 902995L
Authority
NO
Norway
Prior art keywords
fgf protein
stabilized
composition
manufacturing
water
Prior art date
Application number
NO90902995A
Other languages
English (en)
Other versions
NO902995D0 (no
Inventor
Yohko Akiyama
Minoru Yoshioka
Nobuyuki Kitamori
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO902995D0 publication Critical patent/NO902995D0/no
Publication of NO902995L publication Critical patent/NO902995L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Fodder In General (AREA)
NO90902995A 1989-07-07 1990-07-04 Stabilisert fgf sammensetning samt fremstilling derav. NO902995L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP17622889 1989-07-07
JP13633390 1990-05-24

Publications (2)

Publication Number Publication Date
NO902995D0 NO902995D0 (no) 1990-07-04
NO902995L true NO902995L (no) 1991-01-08

Family

ID=26469955

Family Applications (1)

Application Number Title Priority Date Filing Date
NO90902995A NO902995L (no) 1989-07-07 1990-07-04 Stabilisert fgf sammensetning samt fremstilling derav.

Country Status (14)

Country Link
US (1) US5189148A (no)
EP (1) EP0406856B1 (no)
JP (1) JP2536247B2 (no)
CN (1) CN1049106A (no)
AT (1) ATE102044T1 (no)
AU (1) AU632344B2 (no)
CA (1) CA2020654A1 (no)
DE (1) DE69006947T2 (no)
DK (1) DK0406856T3 (no)
ES (1) ES2062206T3 (no)
FI (1) FI903440A7 (no)
HU (1) HU205862B (no)
IE (1) IE902470A1 (no)
NO (1) NO902995L (no)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5202311A (en) * 1988-08-19 1993-04-13 Children's Medical Center Corporation Stabilized fgf composition
GB9015824D0 (en) * 1990-07-18 1990-09-05 Erba Carlo Spa Stable pharmaceutical compositions containing a fibroblast growth factor
US5714458A (en) * 1990-07-18 1998-02-03 Farmitalia Carlo Erba S.R.L. Stable pharmaceutical compositions containing a fibroblast growth factor
US5500409A (en) * 1990-10-01 1996-03-19 Thomas Jefferson University Method for inhibiting collagen synthesis by keloid fibroblasts
TW209174B (no) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
JPH06508371A (ja) 1991-06-21 1994-09-22 ユニバーシティー オブ シンシナティ 経口投与できる治療用タンパク質及びその製法
US6613332B1 (en) 1991-06-21 2003-09-02 The University Of Cincinnati Oral administration of therapeutic proteins
DE4121043A1 (de) * 1991-06-26 1993-01-07 Merck Patent Gmbh Knochenersatzmaterial mit fgf
CA2080538A1 (en) * 1991-10-21 1993-04-22 Joseph V. Bondi Lyophilized acidic fibroblast growth factor
EP0539087A1 (en) * 1991-10-21 1993-04-28 Merck & Co. Inc. Stabilized topical acidic fibroblast growth factor formulation
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5482929A (en) * 1991-12-26 1996-01-09 Kaken Pharmaceutical Co., Ltd. Composition of stabilized fibroblast growth factor
US7070806B2 (en) * 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5348941A (en) * 1992-04-01 1994-09-20 Merck & Co., Inc. Stabilizers for fibroblast growth factors
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
DE4242889A1 (de) * 1992-12-18 1994-06-23 Merck Patent Gmbh Hohlendoprothesen mit Knochenwachstumsfördernder Füllung
JP3349535B2 (ja) * 1993-01-12 2002-11-25 フロイント産業株式会社 球形顆粒の製造方法
US5331095A (en) * 1993-04-12 1994-07-19 Scios Nova Inc. Process for purification of basic fibroblast growth factor
ATE203913T1 (de) * 1993-05-31 2001-08-15 Kaken Pharma Co Ltd Eine gelpräparation aus vernetzter gelatine, die einen basischen wachstumsfaktor für fibroblasten enthält
JPH07112940A (ja) * 1993-08-26 1995-05-02 Takeda Chem Ind Ltd 徐放性非経口投与製剤およびその製造方法
WO1998009645A1 (en) * 1996-09-04 1998-03-12 Dott Research Laboratory Peptide-containing drug compositions for oral administration
US6692961B1 (en) 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
US5851579A (en) * 1996-10-28 1998-12-22 Eastman Chemical Company Aqueous enteric coating compositions
AU4912100A (en) * 1999-06-07 2000-12-28 Fibersugar Aps Particulate fibre composition
US20030228288A1 (en) 1999-10-15 2003-12-11 Scarborough Nelson L. Volume maintaining osteoinductive/osteoconductive compositions
BR0016555A (pt) 1999-12-23 2002-09-17 Pfizer Prod Inc Composições farmacêuticas que proporcionam concentrações acrescidas de droga
JP4711520B2 (ja) * 2000-03-21 2011-06-29 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
US9387094B2 (en) 2000-07-19 2016-07-12 Warsaw Orthopedic, Inc. Osteoimplant and method of making same
US7323193B2 (en) 2001-12-14 2008-01-29 Osteotech, Inc. Method of making demineralized bone particles
US7163691B2 (en) * 2001-10-12 2007-01-16 Osteotech, Inc. Bone graft
FR2836011B1 (fr) * 2002-02-20 2004-05-14 Goemar Lab Sa Agent pour la stimulation des defenses naturelles des plantes et procede pour sa mise en oeuvre
CA2481214A1 (en) * 2002-04-01 2003-10-09 Kaken Pharmaceutical Co., Ltd. Viscous preparation for dental use containing basic fibroblast growth factor
KR20060031808A (ko) 2003-06-11 2006-04-13 오스테오테크, 인코포레이티드 뼈 임플란트 및 그의 제조 방법
ES2404682T3 (es) 2003-12-11 2013-05-28 Isto Technologies Inc. Sistema de cartílago particulado
US20070003541A1 (en) * 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for therapeutics
US20070128685A1 (en) * 2005-07-01 2007-06-07 Rodolfo Faudoa Methods and compositions for cell culture
US20070004036A1 (en) * 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for keratinocyte culture
AU2006282754A1 (en) 2005-08-26 2007-03-01 Zimmer, Inc. Implants and methods for repair, replacement and treatment of joint disease
WO2007056671A1 (en) 2005-11-02 2007-05-18 Osteotech, Inc. Hemostatic bone graft
US8163549B2 (en) 2006-12-20 2012-04-24 Zimmer Orthobiologics, Inc. Method of obtaining viable small tissue particles and use for tissue repair
US20080154233A1 (en) * 2006-12-20 2008-06-26 Zimmer Orthobiologics, Inc. Apparatus for delivering a biocompatible material to a surgical site and method of using same
AU2008240191B2 (en) 2007-04-12 2013-09-19 Zimmer, Inc. Compositions and methods for tissue repair
US8722075B2 (en) 2008-10-24 2014-05-13 Warsaw Orthopedic, Inc. Compositions and methods for promoting bone formation
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
AU2013240972A1 (en) * 2012-03-30 2014-10-30 Ajinomoto Co., Inc. Culture medium for proliferating stem cell, which contains sulfated compound
US20140178343A1 (en) 2012-12-21 2014-06-26 Jian Q. Yao Supports and methods for promoting integration of cartilage tissue explants
ES2824479T3 (es) 2015-11-27 2021-05-12 Univ Masarykova Polipéptido FGF2 termoestable, utilización del mismo
JP2021138648A (ja) * 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
EP4183796A1 (en) 2021-11-19 2023-05-24 Enantis s.r.o. Thermostable fgf10 polypeptide or fragment thereof use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4717717A (en) * 1986-11-05 1988-01-05 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
NZ222413A (en) * 1986-11-05 1991-06-25 Ethicon Inc Compositions containing a polypeptide growth factor and a water-soluble cellulose polymer stabiliser
JP2526965B2 (ja) * 1987-02-24 1996-08-21 武田薬品工業株式会社 ムテイン,dnaおよびその用途
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
NZ226170A (en) * 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor

Also Published As

Publication number Publication date
CA2020654A1 (en) 1991-01-08
US5189148A (en) 1993-02-23
FI903440A7 (fi) 1991-01-08
NO902995D0 (no) 1990-07-04
JP2536247B2 (ja) 1996-09-18
DK0406856T3 (da) 1994-07-04
ATE102044T1 (de) 1994-03-15
AU5879990A (en) 1991-01-10
IE902470A1 (en) 1991-02-13
JPH04128239A (ja) 1992-04-28
EP0406856A3 (en) 1991-04-10
DE69006947D1 (de) 1994-04-07
AU632344B2 (en) 1992-12-24
FI903440A0 (fi) 1990-07-06
CN1049106A (zh) 1991-02-13
EP0406856B1 (en) 1994-03-02
EP0406856A2 (en) 1991-01-09
HU205862B (en) 1992-07-28
ES2062206T3 (es) 1994-12-16
HUT54895A (en) 1991-04-29
DE69006947T2 (de) 1994-08-25
HU904116D0 (en) 1990-12-28

Similar Documents

Publication Publication Date Title
NO902995L (no) Stabilisert fgf sammensetning samt fremstilling derav.
SE9002522L (sv) Metod foer framstaellning av en farmaceutisk komposition i form av mikropartiklar
ZA907338B (en) Thienylcarboxylates of amino alcohols
AU1470292A (en) Stabilized factor viii preparations
NO903898D0 (no) Fremgangsmaate for igjenplugging av en sone i en broenn.
NO892217L (no) Manoevreringsanordning for lasteskuffe.
ES2068919T3 (es) Preparaciones nematicidas.
ATE140962T1 (de) Dns-klone von menschlichem thrombomodulin
DE69001573D1 (de) Zusammensetzungen zur herstellung von in dosisformen aktiven vitaminen d3 sowie verfahren zur herstellung stabiler, in dosisformen aktiver vitamine d3 unter deren verwendung.
BG37376A3 (en) Method for preparing salts of benzothiazine dioxide
ATE139531T1 (de) Arylsubstituierte rhodaninderivate
DE68900210D1 (de) Pyranobenzoxadiazolderivate, herstellung, verwendung und diese enthaltende zubereitungen.
DE3886936D1 (de) 2,5,6,7-TETRANOR-4,8-INTER-m-PHENYLEN 2-PGI-DERIVATE, VERFAHREN ZUR HERSTELLUNG UND DEREN VERWENDUNG.
EP0254239A3 (en) Optically pure 1,3-dioxenones, methods for preparing same and use thereof
DE69018816D1 (de) Aminosäurederivate.
DE69104299D1 (de) Verfahren zur Herstellung von 2,6-Di-t-butyl-4-merkaptophenol.
AU6764790A (en) 13-beta-phenethylthio-milbemycin derivatives
FI875787A7 (fi) Foerfarande foer framstaellning av lipofila aminosyraderivat, samt lipofila aminosyraderivat.
FI880081A7 (fi) 2,1-bensotiazepin-2,2-dioxid-5 -karboxylsyraderivat.
SE8605535D0 (sv) Cellsystem, dess framstellning och anvendning
IT8619653A0 (it) Procedimento per la produzione di bussole a struttura perfezionara, per l'unione di parti in legno.
ATE102207T1 (de) 1,1-dioxo-cephem-4-carbothiolsaeure-derivate.
FI892339L (fi) Foerfarande foer framstaellning av 3/4-brom-2-fluorfenyl) metyl/-3,4-dihydro-4-oxo-1-ftalazinaettiksyra.
NO890473L (no) Analogifremgangsmaate for fremstilling av 6,6-ethylen-15,16-methylen-3-oxo-17alfa-pregn-4-en-21,17-carbolactoner.
NO901860D0 (no) Innkapslet syresammensetning samt fremgangsmaate for fremstilling av slik syresammensetning.